This page will host Events plug-in for all Clarion and trade events.

Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

518.68 +2.37 (+0.46%)
Official Closing Price Updated: 4:15 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its non-GAAP profit of $6.41 per... 
Via StockStory
News headline image
Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It ↗
The company is working through a patent battle that could seriously hamper sales of its new drug. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Excels as a High-Quality Pick in the Caviar Cruise Stock Screen ↗
United Therapeutics Corp (UTHR) excels in the Caviar Cruise stock screen, showcasing strong revenue growth, high ROIC, robust cash flow, and a debt-free balance sheet—ideal for long-term investors. 
Via Chartmill
News headline image
Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Fits Peter Lynch’s Growth at a Reasonable Price (GARP) Strategy ↗
UNITED THERAPEUTICS CORP (UTHR) aligns with Peter Lynch's GARP strategy, boasting steady earnings growth (16.88% EPS), low PEG (0.70), zero debt, and strong profitability (17.31% ROE). A solid biotech... 
Via Chartmill
News headline image
Earnings Scheduled For July 30, 2025 ↗
 
Via Benzinga
News headline image
Preview: United Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Joby Aviation Soars Amidst eVTOL Hype, Signaling a New Era for Air Mobility
Joby Aviation (NYSE: JOBY) has recently experienced a significant surge in its stock value, fueled by a burgeoning "aviation buzz" surrounding the electric vertical takeoff and landing (eVTOL) aircraft... 
Via MarketMinute
Topics Economy Emissions
News headline image
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
News headline image
Forecasting The Future: 8 Analyst Projections For United Therapeutics ↗
 
Via Benzinga
News headline image
Earnings Summary on United Therapeutics ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
United Therapeutics Stock Slides On Q2 Earnings: The Details ↗
United Therapeutics Corp (NASDAQ:UTHR) reported second-quarter financial results before the market open on Wednesday. Here's a rundown of the report. 
Via Benzinga
News headline image
United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its GAAP profit of $6.41 per share... 
Via StockStory
News headline image
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
What To Expect From United Therapeutics’s (UTHR) Q2 Earnings
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? ↗
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it. 
Via Investor's Business Daily
News headline image
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Prime Value Pick with Strong Fundamentals and Undervalued Potential ↗
UNITED THERAPEUTICS CORP (UTHR) is a top value stock with strong fundamentals—low P/E, high profitability, zero debt, and steady growth—making it a standout in biotech. 
Via Chartmill
News headline image
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the... 
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
From United Therapeutics Corporation
Via Business Wire
News headline image
Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Moderna (NASDAQ:MRNA) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock with Impressive Fundamentals and 2 to Keep Off Your Radar
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including BioMarin Pharmaceutical (NASDAQ:BMRN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Strong Candidate for GARP Investors ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) offers strong growth, profitability, and an attractive valuation, making it a solid pick for GARP investors following Peter Lynch's strategy. 
Via Chartmill
News headline image
1 Value Stock with Impressive Fundamentals and 2 to Turn Down
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
News headline image
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - A Potential Undervalued Biotech Stock ↗
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a financially healthy biotech stock with strong profitability and an undervalued price. Its low P/E and high margins make it a candidate for value investors. 
Via Chartmill
News headline image
1 Mid-Cap Stock with Exciting Potential and 2 to Ignore
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
News headline image
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
Disney To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
From United Therapeutics Corporation
Via Business Wire
News headline image
United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
From United Therapeutics Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.